<DOC>
	<DOC>NCT02423538</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral doses of SHR0302 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of SHR0302 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.</brief_summary>
	<brief_title>First-in-Human Single Ascending Dose of SHR0302</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Healthy subjects, age 1845 years (inclusive); The weight of the subject should be more than 50 kg, body mass index (BMI = weight/height squared (kg/m2)) within the range of 19 to 24. Any condition that might interfere with the procedures or tests in the study History of heart failure or renal insufficiency Smoking; Drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>